Capitalization 25.76B 3.54B 274B P/E ratio 2024 *
36.1x
P/E ratio 2025 * 21.9x
Enterprise value 28.63B 3.94B 305B EV / Sales 2024 *
6.46x
EV / Sales 2025 * 4.96x
Free-Float
49.33%
Yield 2024 *
0.38%
Yield 2025 * 0.46%
More valuation ratios * Estimated data
Dynamic Chart
1 day-4.58%
1 week-5.37%
Current month-6.87%
1 month-15.31%
3 months-10.11%
6 months+6.02%
Current year-18.06%
More quotes
1 week
43.14
Extreme 43.14
46.06
1 month
41.43
Extreme 41.43
49.90
Current year
32.10
Extreme 32.1
52.77
1 year
32.10
Extreme 32.1
62.90
3 years
30.53
Extreme 30.53
85.49
5 years
30.53
Extreme 30.53
204.41
10 years
30.53
Extreme 30.53
204.41
More quotes
Manager TitleAgeSince
Chief Executive Officer 47 31/12/07
Director of Finance/CFO 45 19/07/20
Director/Board Member 44 31/12/18
Director TitleAgeSince
Founder 76 16/06/98
Chief Executive Officer 47 31/12/07
Chairman 46 31/12/04
More insiders

Biopharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-4.58%-5.37%+2.91%-46.75% 3.71B
+0.96%+1.39%+16.87%+6.36% 99.18B
0.00%+2.91%+13.37%-5.04% 43.49B
-1.03%-0.32%-18.95%-31.07% 33B
+0.87%+1.75%+76.97%+60.88% 29.72B
-1.03%-1.70%-3.75%+9.59% 16.2B
+0.94%+2.81%+2.57%-17.02% 14.66B
-7.39%-2.37%+2.35%-46.82% 12.88B
+7.95%+4.40%+548.46%+296.75% 10.11B
+2.15%+6.04%+41.46%+71.90% 9.22B
Average -0.12%+0.07%+68.23%+29.88% 27.22B
Weighted average by Cap. +0.27%+0.31%+36.23%+14.65%
See all sector performances

Financials

Ratios2024 *2025 *
Net sales 3.63B 499M 38.66B 4.56B 627M 48.57B
Net income 710M 97.67M 7.57B 1.17B 161M 12.47B
Net Debt -2.33B -321M -24.88B -3.15B -433M -33.54B
More financial data * Estimated data
Logo Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.
Employees
4,482
Calendar
More about the company
Date Price Change Volume
23/07/24 43.14 ¥ -4.58% 7,387,080
22/07/24 45.21 ¥ -0.53% 4,798,835
19/07/24 45.45 ¥ +0.33% 4,715,360
18/07/24 45.30 ¥ -0.07% 4,420,532
17/07/24 45.33 ¥ -0.57% 3,601,685

End-of-day quote Shanghai S.E., July 22, 2024

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
43.14CNY
Average target price
65.00CNY
Spread / Average Target
+50.67%
Consensus
  1. Stock Market
  2. Equities
  3. 603087 Stock